Comparison of GFP-Expressing Imageable XXXX Models of @entity1 @entity1721 Established in Various Anatomical Sites.

@entity1 @entity5 @entity19 @entity1721 @entity42660 @entity418 @entity3
BACKGROUND/AIMS: @entity1721 ( @entity1721 ) is a recalcitrant @entity5 . @entity19 models of this disease could be used for discovery of more effective therapy for @entity1721 . MATERIALS AND METHODS: The green fluorescent protein (GFP)-expressing @entity1 @entity418 @entity42660 cell line was established with a lentiviral expression system. Subsequently, @entity19 were injected subcutaneously, intracardiac or intravenously, or orthotopically implanted with @entity42660 -GFP cells. @entity5 growth and @entity3 were examined by fluorescence in vivo imaging or by open fluorescence imaging after autopsy. RESULTS: Four different @entity19 xenograft models of @entity1721 expressing GFP were established. In the subcutaneous model, @entity5 growth was monitored in real-time by whole-body fluorescence imaging. No @entity3 was observed in the subcutaneous or surgical orthotopic implantation model. By 55 days after implantation, all @entity19 had developed @entity418 , but without detectable @entity3 . In contrast, experimental @entity3 occurred in the intracardiac and intravenous models. In the intravenous injection model, the lung was the sole organ of experimental @entity3 . In the intracardiac model, extensive experimental @entity3 occurred in the bone, brain and lung. CONCLUSION: The @entity19 xenograft models of @entity1721 developed in the present study can provide a means of discovering more effective therapy of this recalcitrant type of @entity5 .
